With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise. As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Va ...

Closing Remarks Terrie Curran, President & Chief Executive Officer Question & Answer FOURTH QUARTER & FULL YEAR 2023 EARNINGS CONFERENCE CALL MARCH 2024 NASDAQ: PHAT Today's Agenda Business Update Terrie Curran, President & Chief Executive Officer US Commercial Launch Progress Martin Gilligan, Chief Commercial Officer Fourth Quarter & Full Year 2023 Results Molly Henderson, Chief Financial & Business Officer Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly H ...

FIRST QUARTER 2024 EARNINGS CONFERENCE CALL MAY 2024 NASDAQ: PHAT Today's Agenda Business Update Terrie Curran, President & Chief Executive Officer US Commercial Launch Progress Martin Gilligan, Chief Commercial Officer First Quarter 2024 Results Molly Henderson, Chief Financial & Business Officer Closing Remarks Terrie Curran, President & Chief Executive Officer Question & Answer Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly Henderson, Chief Financial & ...

THIRD QUARTER 2024 EARNINGS CONFERENCE CALL NOVEMBER 2024 NASDAQ: PHAT Closing Remarks Terrie Curran, President & Chief Executive Officer Question & Answer Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly Henderson, Chief Financial & Business Officer Azmi Nabulsi, Chief Operating Officer Today's Agenda Business Update Terrie Curran, President & Chief Executive Officer US Commercial Launch Progress Martin Gilligan, Chief Commercial Officer Third Quarter 2024 ...

FOURTH QUARTER & FULL YEAR 2024 EARNINGS CONFERENCE CALL MARCH 2025 Closing Remarks Terrie Curran, President & Chief Executive Officer Question & Answer Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly Henderson, Chief Financial & Business Officer Azmi Nabulsi, Chief Operating Officer NASDAQ: PHAT Today's Agenda Business Update Terrie Curran, President & Chief Executive Officer US Commercial Launch Progress Martin Gilligan, Chief Commercial Officer Fourth Qu ...

FIRST QUARTER 2025 EARNINGS CONFERENCE CALL Molly Henderson, Chief Financial & Business Officer Robert Breedlove, VP of Finance & Principal Accounting Officer Closing Remarks Steven Basta, President & Chief Executive Officer MAY 2025 NASDAQ: PHAT Today's Agenda Business Update Steven Basta, President & Chief Executive Officer Q1 2025 Commercial & Financial Results 2 Safe harbor This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this p ...

CHANGING THE LANDSCAPE IN GI Going beyond to advance treatments for patients with acid-related disorders Corporate Overview Safe harbor statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing and magnitude of planned operating expense reductions and ability to achieve revenue growth and profit from operations and the timing thereof; planned operational changes and organ ...

Phathom Pharmaceuticals (PHAT) FY Conference June 11, 2025 10:40 AM ET Speaker0 Okay. We'll continue with the next session. Good morning, everyone. I'm Paul Choi, and I cover the biotech sector here at Goldman Sachs. It's my pleasure to have Fathom Pharmaceuticals here for our next session and Steve Fosta, CEO, to my immediate left. Maybe what we'll do is kick it off by letting Steve kinda introduce himself, maybe provide a little bit of background. There has been some changes at at Fathom recently, and so ...

I've been keeping a close eye on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT ) for quite some time. I like what they do; their main focus is on gastrointestinal disorders, and they have a pretty promising drugI’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like ...

Shares of Phathom Pharmaceuticals, Inc. (PHAT) have gained 184.1% over the past four weeks to close the last trading session at $8.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.50 indicates a potential upside of 107.4%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.09. While the lowest estimate of $5 indicates a 44% decline f ...